VÉRONIQUE MAINFROID
Proteomics Product Manager, Eurogentec S.A.

QUANTITATIVE PROTEOMIC FOR CLINIC DIAGNOSTIC
Despite the identification and validation of numerous potential biomarkers for medical diagnostic, only few of them actually progressed towards clinical use. ELISA remaining the gold standard to quantify proteins, it is often limited to the lack of availability of antibodies with high specificity. The development of more direct detection methods aims at solving this intrinsic issue linked with immunoassays. Indeed, over the last decade, mass spectrometry (MS)-based quantitative proteomics has gained considerable interest (1), as it is the most promising technology allowing amino acid-based biomarker quantification. As such, Multiple Reaction Monitoring (MRM) is considered today as a major technology for accurate quantitative proteomics (2). Moreover, it is well adapted to multiplexing and to high-throughput assays. MRM uses the strategy based on stable isotope-labeled standards for absolute quantification.

MASS SPECTROMETRY (MS)-BASED QUANTITATIVE PROTEOMICS
Because quantitative proteomics relies on the ability to detect small changes in protein abundance, ...